INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS);UNIVERSITE DE LILLE 2, UNIVERSITE DU DROIT ET DE LA SANTE;THE LEIDEN UNIVERSITY M
发明人:
Francois TROTTEIN,Christelle FAVEEUW,Elodie MACHO FERNANDEZ,Luis Javier CRUZ RICONDO
申请号：
US16751638
公开号：
US20200230164A1
申请日:
2020.01.24
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3-dendritic cells.
